1. Home
  2. TMP vs ERAS Comparison

TMP vs ERAS Comparison

Compare TMP & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tompkins Financial Corporation

TMP

Tompkins Financial Corporation

HOLD

Current Price

$75.92

Market Cap

1.2B

Sector

Finance

ML Signal

HOLD

Logo Erasca Inc.

ERAS

Erasca Inc.

HOLD

Current Price

$14.36

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TMP
ERAS
Founded
1836
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.0B
IPO Year
1996
2021

Fundamental Metrics

Financial Performance
Metric
TMP
ERAS
Price
$75.92
$14.36
Analyst Decision
Hold
Strong Buy
Analyst Count
1
13
Target Price
$74.00
$11.38
AVG Volume (30 Days)
46.0K
4.1M
Earning Date
04-24-2026
03-12-2026
Dividend Yield
3.63%
N/A
EPS Growth
126.16
36.23
EPS
11.24
N/A
Revenue
$75,742,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$7.94
N/A
P/E Ratio
$6.59
N/A
Revenue Growth
N/A
N/A
52 Week Low
$54.16
$1.01
52 Week High
$86.95
$16.14

Technical Indicators

Market Signals
Indicator
TMP
ERAS
Relative Strength Index (RSI) 48.88 55.80
Support Level $72.14 $1.50
Resistance Level $77.33 $16.14
Average True Range (ATR) 1.97 1.09
MACD -0.03 -0.23
Stochastic Oscillator 63.80 43.72

Price Performance

Historical Comparison
TMP
ERAS

About TMP Tompkins Financial Corporation

Tompkins Financial Corp is a Financial Holding Company. It has three business segments, consisting of banking, insurance and wealth management. It offers various products and services, including commercial and consumer banking, leasing, trust and investment management, financial planning and wealth management, and insurance. Insurance is comprised of property and casualty insurance services and employee benefit consulting. Wealth management activities include the results of the company's trust, financial planning, and wealth management services. The company generates majority of its revenue from Banking segment.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

Share on Social Networks: